| 1 |
34265801 |
10.1097/PAS.0000000000001780 |
2022 |
Plasticity of Mature B Cells Between Follicular and Classic Hodgkin Lymphomas: A Series of 22 Cases Expanding the Spectrum of Transdifferentiation. |
XPO1 |
| 2 |
34493477 |
10.1016/j.clml.2021.07.017 |
2022 |
Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma Subtypes. |
XPO1 |
| 3 |
35014928 |
10.1080/10428194.2021.2020779 |
2022 |
Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies. |
XPO1 |
| 4 |
35078739 |
10.1016/j.clml.2021.12.016 |
2022 |
Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL Study. |
XPO1 |
| 5 |
35263209 |
10.1080/10428194.2022.2047674 |
2022 |
Long-term follow up of relapsed/refractory non-Hodgkin lymphoma patients treated with single-agent selinexor - a retrospective, single center study. |
XPO1 |
| 6 |
35361554 |
10.1016/j.clml.2022.01.014 |
2022 |
Guidance for Use and dosing of Selinexor in Multiple Myeloma in 2021: Consensus From International Myeloma Foundation Expert Roundtable. |
XPO1 |
| 7 |
35367710 |
10.1016/j.ejmech.2022.114257 |
2022 |
Design, synthesis and biological evaluation of sulfonamides inhibitors of XPO1 displaying activity against multiple myeloma cells. |
XPO1 |
| 8 |
35432603 |
10.1177/17588359221087555 |
2022 |
A phase 1 study of the safety, pharmacokinetics and pharmacodynamics of escalating doses followed by dose expansion of the selective inhibitor of nuclear export (SINE) selinexor in Asian patients with advanced or metastatic malignancies. |
XPO1 |
| 9 |
35477814 |
10.1007/s10637-022-01250-6 |
2022 |
Exportin-1 is critical for cell proliferation and survival in adult T cell leukemia. |
XPO1 |
| 10 |
35489384 |
10.1016/j.yexcr.2022.113180 |
2022 |
Prognostic and therapeutic significance of XPO1 in T-cell lymphoma. |
XPO1 |
| 11 |
35668193 |
10.1038/s43018-022-00394-x |
2022 |
P2RY2-AKT activation is a therapeutically actionable consequence of XPO1 inhibition in acute myeloid leukemia. |
XPO1 |
| 12 |
36001451 |
10.1097/PAS.0000000000001956 |
2022 |
Targeted Mutational Profiling Reveals Clonal Relationships in Metachronous Occurrence of Classic Hodgkin and Mediastinal Large B-Cell Lymphomas. |
XPO1 |
| 13 |
32079702 |
10.3324/haematol.2019.237719 |
2021 |
Targeted genotyping of circulating tumor DNA for classical Hodgkin lymphoma monitoring: a prospective study. |
XPO1 |
| 14 |
32961552 |
10.1182/blood.2020007507 |
2021 |
Mutational landscape of gray zone lymphoma. |
XPO1 |
| 15 |
32972802 |
10.1016/j.blre.2020.100758 |
2021 |
Selinexor, selective inhibitor of nuclear export: Unselective bullet for blood cancers. |
XPO1 |
| 16 |
33173198 |
10.1038/s41571-020-00442-4 |
2021 |
The nuclear export protein XPO1 - from biology to targeted therapy. |
XPO1 |
| 17 |
33263441 |
10.1080/17474086.2021.1856652 |
2021 |
Development of molecular intervention strategies for B-cell lymphoma. |
XPO1 |
| 18 |
33563902 |
10.1038/s41408-021-00409-3 |
2021 |
XPO1 inhibitors represent a novel therapeutic option in Adult T-cell Leukemia, triggering p53-mediated caspase-dependent apoptosis. |
XPO1 |
| 19 |
33785483 |
10.1158/1078-0432.CCR-20-4929 |
2021 |
Selinexor in Combination with R-CHOP for Frontline Treatment of Non-Hodgkin Lymphoma: Results of a Phase I Study. |
XPO1 |
| 20 |
33928519 |
10.1007/s40262-021-01016-y |
2021 |
Pharmacokinetics of Selinexor: The First-in-Class Selective Inhibitor of Nuclear Export. |
XPO1 |
| 21 |
33959502 |
10.3389/fonc.2021.638897 |
2021 |
c-Rel Is the Pivotal NF-κB Subunit in Germinal Center Diffuse Large B-Cell Lymphoma: A LYSA Study. |
XPO1 |
| 22 |
34051651 |
10.1016/j.jchromb.2021.122781 |
2021 |
Bioanalysis of selinexor in mouse plasma micro-samples utilizing UPLC-MS/MS. |
XPO1 |
| 23 |
34405005 |
10.7150/jca.60390 |
2021 |
Serial surveillance by circulating tumor DNA profiling after chimeric antigen receptor T therapy for the guidance of r/r diffuse large B cell lymphoma precise treatment. |
XPO1 |
| 24 |
34669417 |
10.1021/acs.jmedchem.1c01145 |
2021 |
Chromosome Region Maintenance 1 (XPO1/CRM1) as an Anticancer Target and Discovery of Its Inhibitor. |
XPO1 |
| 25 |
34926302 |
10.3389/fonc.2021.785635 |
2021 |
Selinexor Enhances NK Cell Activation Against Malignant B Cells <i>via</i> Downregulation of HLA-E. |
XPO1 |
| 26 |
31789821 |
10.1097/PAI.0000000000000820 |
2020 |
EBV-Positive Primary Large B-Cell Lymphoma: The Role of Immunohistochemistry and XPO1 in the Diagnosis of Mediastinal Lymphomas. |
XPO1 |
| 27 |
31822802 |
10.1038/s41379-019-0428-0 |
2020 |
Diagnostic utility of STAT6<sup>YE361</sup> expression in classical Hodgkin lymphoma and related entities. |
XPO1 |
| 28 |
31847605 |
10.1080/13543784.2020.1706087 |
2020 |
Selinexor (KTP-330) - a selective inhibitor of nuclear export (SINE): anti-tumor activity in diffuse large B-cell lymphoma (DLBCL). |
XPO1 |
| 29 |
31885322 |
10.1080/15384101.2019.1706903 |
2020 |
The double dealing of cyclin D1. |
XPO1 |
| 30 |
32045477 |
10.1182/bloodadvances.2019000359 |
2020 |
Venetoclax response is enhanced by selective inhibitor of nuclear export compounds in hematologic malignancies. |
XPO1 |
| 31 |
32527129 |
10.21037/apm-19-430b |
2020 |
Glans metastatic extra-nodal natural killer/T-cell lymphoma, nasal-type with HDAC inhibitor as maintenance therapy: a rare case report with literature review. |
XPO1 |
| 32 |
32536290 |
10.1080/10428194.2020.1775210 |
2020 |
Selinexor for advanced hematologic malignancies. |
XPO1 |
| 33 |
32565964 |
10.3892/ol.2020.11552 |
2020 |
Comprehensive characterization of driver genes in diffuse large B cell lymphoma. |
XPO1 |
| 34 |
32691208 |
10.1007/s11060-020-03580-y |
2020 |
Repolarization of tumor infiltrating macrophages and increased survival in mouse primary CNS lymphomas after XPO1 and BTK inhibition. |
XPO1 |
| 35 |
32826328 |
10.1158/1078-0432.CCR-20-1315 |
2020 |
The XPO1 Inhibitor KPT-8602 Synergizes with Dexamethasone in Acute Lymphoblastic Leukemia. |
XPO1 |
| 36 |
33007990 |
10.3390/cancers12102829 |
2020 |
<i>XPO1</i><sup>E571K</sup> Mutation Modifies Exportin 1 Localisation and Interactome in B-cell Lymphoma. |
XPO1 |
| 37 |
33148342 |
10.1186/s13045-020-00982-3 |
2020 |
XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53. |
XPO1 |
| 38 |
33154951 |
10.3389/fonc.2020.591577 |
2020 |
Genetic and Non-Genetic Mechanisms of Resistance to BCR Signaling Inhibitors in B Cell Malignancies. |
XPO1 |
| 39 |
33202794 |
10.3390/ijms21228553 |
2020 |
Novel Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma. |
XPO1 |
| 40 |
33224395 |
10.14740/jh760 |
2020 |
Molecular Genetic Analysis With Flow Cytometry Sorting Identifies Angioimmunoblastic T-Cell Lymphoma and Concomitant <i>De Novo</i> Myelodysplastic Syndrome Arising From the Same Hematopoietic Progenitor. |
XPO1 |
| 41 |
30108156 |
10.1634/theoncologist.2018-0058 |
2019 |
Comprehensive Genomic Profiling of Hodgkin Lymphoma Reveals Recurrently Mutated Genes and Increased Mutation Burden. |
XPO1 |
| 42 |
30211726 |
10.1097/PAS.0000000000001154 |
2019 |
Cyclin D1-positive Mediastinal Large B-Cell Lymphoma With Copy Number Gains of CCND1 Gene: A Study of 3 Cases With Nonmediastinal Disease. |
XPO1 |
| 43 |
30548996 |
10.1002/hon.2570 |
2019 |
Exportin-1 E571K mutation is a common finding in patients with classical Hodgkin lymphoma. |
XPO1 |
| 44 |
31125526 |
10.1080/17474086.2019.1624158 |
2019 |
Novel targets for the treatment of relapsing multiple myeloma. |
XPO1 |
| 45 |
31296529 |
10.1158/1078-0432.CCR-19-0273 |
2019 |
Eμ-TCL1xMyc: A Novel Mouse Model for Concurrent CLL and B-Cell Lymphoma. |
XPO1 |
| 46 |
31543372 |
10.1016/j.clml.2019.08.011 |
2019 |
Selective Inhibitors of Nuclear Export in the Treatment of Hematologic Malignancies. |
XPO1 |
| 47 |
31752970 |
10.1186/s13045-019-0803-9 |
2019 |
Simultaneous targeting of XPO1 and BCL2 as an effective treatment strategy for double-hit lymphoma. |
XPO1 |
| 48 |
31816062 |
10.1182/bloodadvances.2019001012 |
2019 |
Genomic analyses of flow-sorted Hodgkin Reed-Sternberg cells reveal complementary mechanisms of immune evasion. |
XPO1 |
| 49 |
31850145 |
10.2217/ijh-2019-0009 |
2019 |
Rational targeted therapeutics for double-hit lymphoma. |
XPO1 |
| 50 |
28750570 |
10.1080/10428194.2017.1349899 |
2018 |
Identification of potential ibrutinib combinations in hematological malignancies using a combination high-throughput screen. |
XPO1 |
| 51 |
29501729 |
10.1016/j.cellsig.2018.02.016 |
2018 |
STAT6 is a cargo of exportin 1: Biological relevance in primary mediastinal B-cell lymphoma. |
XPO1 |
| 52 |
29610030 |
10.1016/j.clml.2018.03.003 |
2018 |
Clinical Implications of Targeting XPO1-mediated Nuclear Export in Multiple Myeloma. |
XPO1 |
| 53 |
29650799 |
10.1182/blood-2017-11-814913 |
2018 |
Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma. |
XPO1 |
| 54 |
29653964 |
10.1182/blood-2017-09-806679 |
2018 |
TRRAP is essential for regulating the accumulation of mutant and wild-type p53 in lymphoma. |
XPO1 |
| 55 |
29989027 |
10.18632/oncotarget.25601 |
2018 |
New generation sequencing of targeted genes in the classical and the variant form of hairy cell leukemia highlights mutations in epigenetic regulation genes. |
XPO1 |
| 56 |
30510142 |
10.1158/1535-7163.MCT-17-0789-ATR |
2018 |
XPO1 Inhibitor Selinexor Overcomes Intrinsic Ibrutinib Resistance in Mantle Cell Lymphoma via Nuclear Retention of IκB. |
XPO1 |
| 57 |
31949642 |
|
2018 |
Expression of exportin-1 in diffuse large B-cell lymphoma: immunohistochemistry and TCGA analyses. |
XPO1 |
| 58 |
27780859 |
10.1158/1078-0432.CCR-16-1580 |
2017 |
The Second-Generation Exportin-1 Inhibitor KPT-8602 Demonstrates Potent Activity against Acute Lymphoblastic Leukemia. |
XPO1 |
| 59 |
28196522 |
10.1186/s13045-017-0412-4 |
2017 |
XPO1 in B cell hematological malignancies: from recurrent somatic mutations to targeted therapy. |
XPO1 |
| 60 |
28388555 |
10.18632/oncotarget.16602 |
2017 |
Targeting mantle cell lymphoma metabolism and survival through simultaneous blockade of mTOR and nuclear transporter exportin-1. |
XPO1 |
| 61 |
28468797 |
10.1182/blood-2016-11-750174 |
2017 |
Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma. |
XPO1 |
| 62 |
26608593 |
10.1002/gcc.22328 |
2016 |
Whole exome sequencing of relapsed/refractory patients expands the repertoire of somatic mutations in diffuse large B-cell lymphoma. |
XPO1 |
| 63 |
26819451 |
10.1158/1078-0432.CCR-15-2305 |
2016 |
Next-Generation Sequencing in Diffuse Large B-Cell Lymphoma Highlights Molecular Divergence and Therapeutic Opportunities: a LYSA Study. |
XPO1 |
| 64 |
26883583 |
10.3109/10428194.2016.1139703 |
2016 |
Digital PCR for quantification of recurrent and potentially actionable somatic mutations in circulating free DNA from patients with diffuse large B-cell lymphoma. |
XPO1 |
| 65 |
27312795 |
10.1002/ajh.24451 |
2016 |
Recurrent mutations of the exportin 1 gene (XPO1) and their impact on selective inhibitor of nuclear export compounds sensitivity in primary mediastinal B-cell lymphoma. |
XPO1 |
| 66 |
27479820 |
10.3324/haematol.2016.145102 |
2016 |
Detection and prognostic value of recurrent exportin 1 mutations in tumor and cell-free circulating DNA of patients with classical Hodgkin lymphoma. |
XPO1 |
| 67 |
27693556 |
10.1016/j.canlet.2016.09.016 |
2016 |
Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone. |
XPO1 |
| 68 |
25466285 |
10.1016/j.leukres.2014.10.003 |
2015 |
CRM1 as a new therapeutic target for non-Hodgkin lymphoma. |
XPO1 |
| 69 |
25951043 |
10.1080/15548627.2015.1017192 |
2015 |
The role of STAT3 in autophagy. |
XPO1 |
| 70 |
26340096 |
10.1371/journal.pone.0137210 |
2015 |
Ribosomal Biogenesis and Translational Flux Inhibition by the Selective Inhibitor of Nuclear Export (SINE) XPO1 Antagonist KPT-185. |
XPO1 |
| 71 |
26501108 |
10.1016/j.ebiom.2015.07.041 |
2015 |
Human Exportin-1 is a Target for Combined Therapy of HIV and AIDS Related Lymphoma. |
XPO1 |
| 72 |
24503695 |
10.1371/journal.pone.0087585 |
2014 |
Preclinical evaluation of the novel, orally bioavailable Selective Inhibitor of Nuclear Export (SINE) KPT-335 in spontaneous canine cancer: results of a phase I study. |
XPO1 |
| 73 |
24766216 |
10.1111/cas.12430 |
2014 |
Induction of p53-mediated transcription and apoptosis by exportin-1 (XPO1) inhibition in mantle cell lymphoma. |
XPO1 |
| 74 |
25377562 |
10.1182/blood-2014-04-567636 |
2014 |
Cryptic XPO1-MLLT10 translocation is associated with HOXA locus deregulation in T-ALL. |
XPO1 |
| 75 |
23373539 |
10.1111/bjh.12231 |
2013 |
KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia. |
XPO1 |
| 76 |
23970380 |
10.1182/blood-2013-04-495374 |
2013 |
Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias. |
XPO1 |
| 77 |
24159164 |
10.1182/blood-2013-09-523670 |
2013 |
Redirecting traffic using the XPO1 police. |
XPO1 |
| 78 |
18246793 |
|
2007 |
[Expression and relationship of p27(kip1) and its related molecules Jab1 and CRM1 during proliferation of lymphoma cells U937]. |
XPO1 |
Datasets
Models
